title: Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression.
authors.affiliation: Department of Nephrology, Laiko General Hospital, Athens, Greece.
authors.forename: J N
authors.initials: JN
authors.lastname: Boletis
authors.forename: H
authors.initials: H
authors.lastname: Theodoropoulou
authors.forename: T
authors.initials: T
authors.lastname: Hiras
authors.forename: D
authors.initials: D
authors.lastname: Stamatiadis
authors.forename: M
authors.initials: M
authors.lastname: Darema
authors.forename: E
authors.initials: E
authors.lastname: Psimenou
authors.forename: C
authors.initials: C
authors.lastname: Stathakis
authors.forename: A
authors.initials: A
authors.lastname: Kostakis
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D003404:Creatinine; D008775:Methylprednisolone